External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Thematic (Sector/Industry)

<ul><li>Dr Reddy’s Laboratories: EBITDA grew (14% YoY) as +13% YoY sales growth (-3% QoQ US, +5% YoY in EU, +9% YoY EMs, and +34% YoY in RoW, India declined 12% YoY, adjusted growth was at 11%), steady gross margin (+65 bps YoY) and muted staff cost were offset by higher R&amp;D/SG&amp;A (+28/+22% YoY)</li><li>DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next few years)</li><li>The company expects India to see steady growth in FY25, led by new launches, scale-up in key therapies, and in-licensing opportunities</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Dr Reddy’s Laboratories: EBITDA grew (14% YoY) as +13% YoY sales growth (-3% QoQ US, +5% YoY in EU, +9% YoY EMs, and +34% YoY in RoW, India declined 12% YoY, adjusted growth was at 11%), steady gross margin (+65 bps YoY) and muted staff cost were offset by higher R&amp;D/SG&amp;A (+28/+22% YoY)DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next few years)The company expects India to see steady growth in FY25, led by new launches, scale-up in key therapies, and in-licensing opportunitiesContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Dr Reddy’s Laboratories, Lupin, IRB Infra, Max Financial

<ul><li>Titan: Titan’s top line grew 22% YoY to INR 141.6bn (HSIE: INR 148.2bn)</li><li>Jewellery (ex-bullion) sales grew 24% YoY to INR125.6bn (in-line)</li><li>Festive purchases resulted in double-digit buyer growth in jewellery, moderation was seen after Nov-23 though Consolidated EBITDAM contracted 55 bps YoY to 11% (in-line)</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Titan: Titan’s top line grew 22% YoY to INR 141.6bn (HSIE: INR 148.2bn)Jewellery (ex-bullion) sales grew 24% YoY to INR125.6bn (in-line)Festive purchases resulted in double-digit buyer growth in jewellery, moderation was seen after Nov-23 though Consolidated EBITDAM contracted 55 bps YoY to 11% (in-line)Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Titan, Astral, Aditya Birla Capital, IRB Infra

<ul><li>Axis Bank: Axis Bank (AXSB) reported in-line results, led by healthy loan growth (+4.5% QoQ) and a sharp improvement in asset quality</li><li>NIMs were flat sequentially at 4.11% with the deposit book continuing to reprice on the back of accelerated TD mobilisation and decline in CASA deposits (-118bps QoQ to 44.4%)</li><li>This led to a further increase in the loan-to-deposit ratio to ~94%, which appears increasingly untenable</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Axis Bank: Axis Bank (AXSB) reported in-line results, led by healthy loan growth (+4.5% QoQ) and a sharp improvement in asset qualityNIMs were flat sequentially at 4.11% with the deposit book continuing to reprice on the back of accelerated TD mobilisation and decline in CASA deposits (-118bps QoQ to 44.4%)This led to a further increase in the loan-to-deposit ratio to ~94%, which appears increasingly untenableContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Axis Bank, Tech Mahindra, Jubilant FoodWorks, Sonata Software

<ul><li>The big news is that not much has changed in the past few months</li><li>Most of the demand indicators are trailing 10-15% below levels at the beginning of the year and only slightly better than the July lows, the supply-side factors remain favourable, supporting operational resilience despite soft growth</li><li>In Q2FY24, the IT sector is expected to deliver a soft quarter, although Q2 has historically been a seasonally strong quarter.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

The big news is that not much has changed in the past few monthsMost of the demand indicators are trailing 10-15% below levels at the beginning of the year and only slightly better than the July lows, the supply-side factors remain favourable, supporting operational resilience despite soft growthIn Q2FY24, the IT sector is expected to deliver a soft quarter, although Q2 has historically been a seasonally strong quarter.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

<ul><li>Maruti Suzuki: Maruti Suzuki’s (MSIL) Q1FY24 PAT at INR 24.8bn was ahead of our estimate of INR 23.5bn even as a lower-than-expected margin was offset by higher-than-expected other income</li><li>Over the last three quarters, MSIL has been on an aggressive launch spree, having launched four new models, viz., Grand Vitara, Jimny, Fronx and the Invicto, in a bid to recover its lost share in UVs, which has now recovered to 23% in Q1 (from 17% YoY) MSIL is now again the market leader in UV segment</li><li>The recent success of GV (9-10k units per month) and the higher-than-expected order bookings for Invicto are a case in point customers are considering Maruti’s products as “worthy contenders” even in the &gt;Rs1500k segment, where few investors were so far doubting the company’s “right to win”</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Maruti Suzuki: Maruti Suzuki’s (MSIL) Q1FY24 PAT at INR 24.8bn was ahead of our estimate of INR 23.5bn even as a lower-than-expected margin was offset by higher-than-expected other incomeOver the last three quarters, MSIL has been on an aggressive launch spree, having launched four new models, viz., Grand Vitara, Jimny, Fronx and the Invicto, in a bid to recover its lost share in UVs, which has now recovered to 23% in Q1 (from 17% YoY) MSIL is now again the market leader in UV segmentThe recent success of GV (9-10k units per month) and the higher-than-expected order bookings for Invicto are a case in point customers are considering Maruti’s products as “worthy contenders” even in the &gt;Rs1500k segment, where few investors were so far doubting the company’s “right to win”Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

HSIE Results Daily: Maruti Suzuki, Sonata Software, Multi Commodity Exchange

India

Sonata Software Limited operates an Information Technology company, which provides software products, development services, IT consulting, and a number of business solutions services.  The Group exports its products primarily to the U.S.A., Europe and Asia.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sonata Software (SSOF IN)

HSIE Results Daily: Dr Reddy’s Laboratories, Lupin, IRB Infra, Max Financial

DRRD expects to sustain growth in the US over the next few years with steady traction in gRevlimid and new launches (20+ launches p.a for the next...

HDFC Securities

HSIE Results Daily: Titan, Astral, Aditya Birla Capital, IRB Infra

Festive purchases resulted in double-digit buyer growth in jewellery, moderation was seen after Nov-23 though Consolidated EBITDAM contracted 55...

HDFC Securities

HSIE Results Daily: Axis Bank, Tech Mahindra, Jubilant FoodWorks, Sonata Software

Axis Bank (AXSB) reported in-line results, led by healthy loan growth (+4.5% QoQ) and a sharp improvement in asset quality

HDFC Securities

IT Sector - Soft Q2, Status Quo Remains

Most of the demand indicators are trailing 10-15% below levels at the beginning of the year and only slightly better than the July lows

HDFC Securities

HSIE Results Daily: Maruti Suzuki, Sonata Software, Multi Commodity Exchange

Maruti Suzuki’s (MSIL) Q1FY24 PAT at INR 24.8bn was ahead of our estimate of INR 23.5bn even as a lower-than-expected margin was offset by higher...

HDFC Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)